TechniBytes

V6.07 Upgrade

I. V6.07 Database/Conversion Changes

1. Conversion of ICD-O-2 Morphologies to ICD-O-3

1. Appropriate conversion flag changes will be completed along with the removal of the '9' code.
2. Optional and Mandatory review reports will be generated based on the SEER ICD-O-2 to ICD-O-3 conversion program.
3. Cases with a Date of Initial Diagnosis of 2001 or later will have the ICD-O-2 morphology and behavior codes deleted.
4. Note: ICR [MRS] did change the SEER conversion program for one code, 9421, in order to comply with Appendix E: Reporting of Juvenile Astrocytoma in ICD-O-3 published in "Guidelines for ICD-O-3 Implementation" dated November 27, 2000. At the time of the conversion, ICD-O-2 histology code '9421' will be converted to a behavior of '3' rather than a '1' as written in the conversion program.
5. Note: ICR [MRS] will require data entry of both the ICD-O-2 and ICD-O-3 histology/behavior codes for cases diagnosed prior to 2001.

2. Removal of Class of Case 'X' from Class of Case table. All existing Class of Case 'X' codes will be converted to '9'.
3. Removal of General Summary Stage 'B' from General Summary Stage table. All existing General Summary Stage 'B' codes will be converted to '9'.
4. The following PCE data will be removed and archived:
   1. Esophagus (PCE 1)
   2. Corpus Uteri (PCE 2)
   3. Bladder (PCE 3)
   4. Thyroid (PCE 4)
   5. Soft Tissue Sarcoma (PCE 5)
   6. Colorectal (PCE 6)
   7. Non-Hodgkin (PCE 7)

   Note: Data from the PCE's will be archived to an Access database.

5. For cases with a primary site of 'C320' [Glottis] laterality will be set to '0 - Not a paired site'.
6. Expired patients with an 'ICD Cause of Death' field completed with '0000' or blank (spaces) will be converted to '7797'.
7. All apostrophes will be replaced with a 'tic' (`) in the following database fields: Patient Last Name, Patient First Name, Patient Middle Name, and Medical Record Number.
8. All apostrophes will be replaced with a 'tic' (`) in the following database fields: Patient Last Name, Patient First Name, Patient Middle Name, and Medical Record Number.
9. Diagnoses with a primary site of 'C141 - Laryngopharynx' (no longer valid) will be changed to primary site 'C139 - Hypopharynx'.
10. If the Surgery Summary of the Primary Site is '00', the Surgical Approach will be converted to '0' and Surgical Margins will be converted to '8'.
11. Surgical Treatment Summary data will be adjusted to summarize Surgery of Primary site independently from Scope of Regional Lymph Node Surgery. All existing summaries will be recalculated.
12. 'Scope of Regional Lymph Node Surgery' and 'Number of Regional Lymph Nodes Removed' field values for Unknown, Brain, Lymphoma, Leukemia cases will be completed with '9' and '99' in all appropriate database fields ('Treatment Summary', 'First Course of Therapy' and 'Subsequent Treatment') regardless of the type of treatment that was given or if no treatment was administered when the accession year is 2000 or later. The former Histology range included only Leukemia [9800-9948] and will be adjusted to include all Hematopoetic histologies [9800-9989]. This adjustment was made in preparation for 2003 changes due to the fact state central registries have begun to modify their edit metafiles in advance of the implementation of 2003 standards.
13. Recalculate 'Best Stage' as Stage 1 for the C53* (Cervix) group stages of A1, A2, B1, B2. Stage A1, A2, B1 and B2.
14. The 'Referred from' and 'Referred to' field data will be modified to reflect the current (11/2001) American College of Surgeons Facility Id Numbers (FIN) table. The FIN table contains the ACS Facility Id Numbers assigned by the COC.

II. V6.07 Table Updates

1. FIN table updated.

1. The table contains the ACS Facility Id Numbers that the COC assigns to each facility.
2. The 'Referred from' and 'Referred to' fields reference the FIN table.

2. Site-Histology Validation table updated to the ICD-O-3 SEER Site/Histology Validation List - 6/14/2001.

1. The table is used to indicate the Site/Histology warnings.
2. The system will no longer perform Site/Histology validation on ICD-O-2 codes.
3. The ICD-O-3 SEER Site/Histology Validation List pdf file may be found on SEER's website:
   http://seer.cancer.gov/Admin/

III. V6.07 Enhancements

A. The ICR [MRS] system is Windows 2000 compliant.

B. On-Line

1. All appropriate displays and edits are modified to run from ICD-O-3 histology/behavior codes.
2. Cross Comparison report displays data fields in data entry screen order. The data field descriptive labels consist of the label used in Online and the actual database name.

C. Reports

1. Case Finding - New option to add Follow-up to Complete, Incomplete and Suspense cases. Appropriate diagnosis data fields will be updated as well.
2. All Standard Filters/Reports are modified to search and report ICD-O-3 morphology information.
3. Follow-up report filtering will determine follow-up eligibility based on ICD-O-2 Histology for cases diagnosed prior to 2001 and based on ICD-O-3 for cases diagnosed on or after 2001.
4. Added a new 'Body System' report format option to appropriate Frequency reports.
   1. The 'Body System' report format is similar to the SEER report format but does NOT exclude in situ, skin, benign and borderline cases from the report counts/totals.
   2. Both the SEER and 'Body System' Reports are based on preliminary SEER Recode Tables for ICD-O-3. They will be revised once the official release of the Recode Tables is available.

D. ICR Query Wizard (formerly QMRS)

1. Query system rewritten to display data reports in Excel. This will provide for ease in re-formatting of reports when desired.
2. ICR Query Wizard provides a mechanism for the export and import of queries between users (Standard data elements only).
3. The following fields have been added to the ICR Query Wizard database:
   1. Race 2-5
   2. Gastric PCE fields
   3. Non-Small Cell Lung PCE fields

E. State Reporting

1. When submitting data to the central registry, there are specific date fields that some central registries prefer submission of unknown date information to a 'guess estimate' date. The collection of unknown date information for central registry reporting will be performed through a separate optional supplemental data entry screen.
2. The selection of the state supplemental screen option is set in the Hospital Default record.
3. The state supplemental screen will appear at the end of the initial abstract. Only date fields that are unknown need to be completed.

F. Multi-Hospital Follow-Up

1. Multi-Hospital Follow-up Data Entry
   1. Follow-up information is added across primaries and hospital databases in accordance with the security matrix.
   2. Matched Primaries - Follow-up data (including treatment) is posted across all hospitals where the primary is duplicated.
   3. UnMatched Primaries - Data is entered (treatments not included) and recorded on a primary-by-primary basis.
2. Multi-Hospital Follow-up Report generation
   1. Ability to produce control reports and letters across databases.
   2. May generate a 'Single' follow-up letter across databases or may generate 'Unique' follow-up contact letters across hospital databases.

IV. V6.07 Resolved Product Issues

1. Repair Productivity Matrix 'bug'. When performing a Diagnosis Transfer, which required a change of an existing primary sequence from '00' to '01', the productivity matrix was not updated. The productivity information for the '00' diagnosis record is lost.
2. Modified 'Best Stage' calculation to adjust for the C53* - Cervix group stages of A1, A2, B1, B2. Stage A1, A2, B1 and B2 will be calculated and published as Stage 1.
3. Breast Size of Tumor and AJCC 'T' edit modified. If the Path descriptor is '4' or '6', Size of Tumor will check the Clinical 'T'. If the Size of Tumor is '99.9', no editing will take place.

1. AJCC Path/Clin 'T' Edits for Breast (taken from p. 117 Vol III Edits) are performed when the primary site is breast (site = C500 - C509) and the AJCC edition is '4' or '5'.
2. Path T = 1, 1A, 1B, 1C then Tumor Size must be greater than '00.0' and less than or equal to '02.0'.
3. Path T = 2, then Tumor Size must be greater than '02.0' and less than or equal to '05.0'.
4. Path T = 3, then Tumor Size must be greater than '05.0' and less than or equal to '99.7'.
5. Path T = 'X' then AJCC Clin T is edited against Tumor Size using Path T edit criteria.

4. 'Scope of Regional Lymph Node Surgery' and 'Number of Regional Lymph Nodes Removed' field values for Unknown, Brain, Lymphoma, Leukemia cases will default to '9' and '99' in the 'Treatment Summary', 'First Course of Therapy' and 'Subsequent Treatment' listings and database fields regardless of the type of treatment that was given or even if no treatment was administered when the accession year is 2000 or later. The former Histology range included only Leukemia [9800-9948] and will be adjusted to include all Hematopoetic histologies [9800-9989].
5. Gastric PCE eligibility criteria adjusted to include histology code '8936' (GIST) with behaviors of '0', '1', '2', and '3'.
6. Date of First Treatment will calculate based on treatment dates for all case statuses and each time a case is recorded. If there are no treatments, the date must be manually entered for Reportable and Complete cases.

Note: ICR [MRS] reserves the right to make changes to the final V6.07 product.

Back to top